Merck Announces Data from Investigational Phase 3 Study on EMEND® (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Undergoing Emetogenic Chemotherapy
Dateline City:
WHITEHOUSE STATION, N.J.
Merck Planning Regulatory Submissions in the U.S. for EMEND® in Pediatric Setting Including New Suspension Formulation in Second Half of 2014
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from a global, investigational Phase 3 study to
evaluate the safety and efficacy of EMEND® (aprepitant) in
the prevention of chemotherapy-induced nausea and vomiting (CINV) in
pediatric cancer patients, aged 6 months to 17 years.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558orClaire Mulhearn, 908-423-7425orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Child Development | Children | Merck | Pediatrics | Pharmaceuticals | Study